To print: Select File and then Print from your browser's menu

Title: Probiotic VSL#3 Could Relieve Some Irritable Bowel Abdominal Bloating

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12656692&dopt=Abstract

Alimentary Pharmacology 2003;17:7:895-904. "A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome"
04/01/2003 03:58:27 PM
By Elda Hauschildt

Probiotic formulation VSL#3 appears promising in relieving abdominal bloating in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Researchers from the Mayo Clinic and Mayo Foundation in Rochester, Minnesota, United States, found that the action was unrelated to alteration in gastrointestinal (GI) or colonic transit in a randomised, controlled trial with 25 diarrhoea-predominant IBS patients. Following a 2-week run-in period, participants were randomly assigned to either VSL#3 or placebo twice daily for eight weeks. Patients underwent pre- and post-treatment measurement of GI transit. They also recorded bowel function and symptoms daily during the 10-week study. No significant differences were observed between treatment groups pre- or post-therapy on measurements of GI transit, bowel function or satisfactory global symptoms. The investigators say that further analysis indicated abdominal bloating was reduced in patients receiving VSL#3. This effect was not seen in patients receiving placebo. "With the exception of changes in abdominal bloating, VSL#3 had no effect on other individual symptoms: abdominal pain, gas and urgency," they report. All patients were able to tolerate the probiotic.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12656692&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.